Introduction {#s1}
============

Metformin and sulfonylureas are two of the most widely prescribed medications for the treatment of type 2 diabetes with millions of users worldwide. Metformin, the first-line drug for the treatment of type 2 diabetes, has a long-standing evidence base for efficacy and safety, is inexpensive, and may reduce the risk of cardiovascular events and death ([@B1]). Similarly, sulfonylureas are extensively used based on their glucose-lowering efficacy, universal local availability and low cost ([@B2]). Yet, there remains significant interindividual variation in the responses to these medications, and, despite our vision of precision medicine, clinicians continue to make therapeutic decisions based on the population average parameters of efficacy and side-effect profile of a given drug, rather than on individual level characteristics.

In recent years, the field of type 2 diabetes and related glycemic traits has experienced an explosion of genetic discovery; there are now ∼100 loci associated with type 2 diabetes or related traits through large-scale genome-wide association studies and high-throughput sequencing technology ([@B3]--[@B8]). Despite our knowledge of the associations of several genetic variants with type 2 diabetes and their involvement in physiological pathways involved in drug response, their impact on pharmacological interventions has not been systematically examined. Similarly, we know that genetic factors influence the glycemic response to metformin, with common genetic variants explaining between 21% and 34% of the variation in metformin response, depending on how glycemic response was measured ([@B9]). However, small pharmacokinetic studies of metformin response have not yielded significant results, and to date only two significant genome-wide efforts of metformin response have been published, yielding minimal results ([@B10],[@B11]). There has also been limited success in pharmacogenetics studies of sulfonylurea response ([@B12]). Overall, there is a crucial need for strategies that integrate physiological and pharmacogenetic information with genetic discoveries to better understand biological pathways and drug response ([@B13]).

The T allele of the intronic single nucleotide polymorphism (SNP) rs7903146 located within the transcription factor 7 like 2 (*TCF7L2*) gene is strongly associated with type 2 diabetes ([@B14],[@B15]). This finding has been consistently replicated across multiple populations including children, and *TCF7L2* remains among the strongest common genetic risk factors for type 2 diabetes ([@B16]--[@B19]). However, our knowledge of the mechanisms for this increased risk still remains uncertain. *TCF7L2* encodes a transcription factor associated with the Wnt/β-catenin signaling pathway and is widely expressed in various tissues ([@B20]). The key effector of the WNT signaling pathway is the transcription factor β-catenin/TCF, formed by heterodimerization of β-catenin and a member of the TCF family. Several potential mechanisms have been posited for the increased type 2 diabetes risk conferred by genetic variation in *TCF7L2*, related to mechanisms both within and beyond the β-cell. These include diminished β-cell mass, impaired proinsulin processing, reduced insulin secretion, and an altered incretin effect. To improve our understanding of the role of common variation in *TCF7L2* in relation to medication response in human participants free of disease and naive to diabetes drugs prospectively, we leveraged our Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). The primary objective of our study was to evaluate the physiologic and hormonal effects of *TCF7L2* genotype before and after interventions that influence glucose physiology using two commonly prescribed medications for type 2 diabetes: the sulfonylurea glipizide and the biguanide metformin. A secondary objective of our study was to evaluate the incretin response in relation to the *TCF7L2* genotype, the strongest common genetic risk factor for type 2 diabetes, as a potential mechanism that contributes to type 2 diabetes risk.

Research Design and Methods {#s2}
===========================

Study Design and Description of Participants {#s3}
--------------------------------------------

The study design and baseline participant characteristics of SUGAR-MGH (Clinical trial reg. no. NCT01762046, [clinicaltrials.gov](clinicaltrials.gov)) have been described in detail previously ([@B21]). Briefly, SUGAR-MGH is a National Institutes of Health (NIH)-funded clinical research study and novel resource of genetic and biochemical data in 1,000 adults who were enrolled at three Boston academic medical centers from 2008 to 2015. Participants were preferentially enrolled if they had risk factors for type 2 diabetes or lifestyle-controlled type 2 diabetes, but had never received antidiabetic therapy. During the study protocol, they were sequentially administered glipizide and metformin, two medications commonly used to treat type 2 diabetes and chosen to perturb two different limbs of the glucose homeostatic system (insulin secretion and insulin action) under basal and hyperglycemic conditions. Plasma glucose and insulin were drawn at regular intervals before and after *1*) a single dose of 5 mg glipizide (visit 1) and *2*) a 75-g oral glucose tolerance test (OGTT) after 2 days of treatment with 500 mg of metformin twice a day. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), proinsulin, and glucagon were measured in a subset of these samples. The SUGAR-MGH protocol was approved by the Partners Human Research Committee, and written informed consent was obtained from all participants. The SUGAR-MGH protocol required two visits to the Clinical Research Center (CRC) and 1 week of active treatment per subject. No participant experienced a hypoglycemia-related serious adverse event, and no participant required intravenous glucose or glucagon to treat hypoglycemia. In this study, we describe findings from the first 608 subjects that were genotyped consecutively of 1,000 subjects who were recruited.

Genotyping {#s4}
----------

DNA was extracted and genotyping performed using the iPLEX-GOLD Assay from Sequenom by allele-specific primer extension of amplified products with detection by mass spectroscopy. Genotype data for SNP rs7903146 (*TCF7L2*) was available for the first 608 participants who completed both visits and took all four doses of metformin. A subset of these participants (150) had GLP-1 and GIP assay measurements.

Measurements {#s5}
------------

A medical history was obtained by the consenting practitioner from all participants; and weight, height, blood pressure, and heart rate were measured at each visit to the CRC. Plasma glucose was measured by a hexokinase assay (Roche, Indianapolis, IN). Insulin level was determined using a radioimmunoassay (Beckman Coulter, Fullerton, CA). The intra-assay coefficient of variability (CV) for the insulin assay was 2.2--4.4% and the interassay CV was 2.9--6.0%. C-peptide was measured by radioimmunoassay (KPED1; Siemens, Erlangen, Germany); glucagon was measured by radioimmunoassay (LINCOplex Kit, HENDO-65K-Rev; Linco Research, St. Charles, MO). The CV of the glucagon assay was 10.9--13.3%. Incretin hormones (GLP-1 and GIP) were measured from blood samples collected in prechilled EDTA tubes containing DPP-IV inhibitor (Millipore, Billerica, MA). Active GLP-1 (7--36,7--37) was measured using the GLP-1 (Active) ELISA Kit (Millipore); total GLP-1 was measured using the GLP-1 (7--36,9--36) ELISA kit from Alpco Immunoassays (Salem, NH); and GIP was measured by using the Human GIP Total ELISA Kit from Millipore.

Statistical Analyses {#s6}
--------------------

The area under the curve (AUC) for insulin and glucagon during the glipizide challenge and for glucose, insulin, GLP-1, and GIP during the OGTT challenge was calculated by the trapezoidal method and adjusted for baseline values. The area over the curve for decreases in glucose during the glipizide challenge was calculated by subtracting AUC by the trapezoidal method from the baseline glucose value at visit 1 × total time for the glipizide challenge. Mean (± SD) or median (interquartile range) is provided for continuous normally or non-normally distributed traits, respectively, unless otherwise specified. Missing data were not imputed. Multilevel mixed-effects linear regression models, with adjustments for age, sex, self-reported race/ethnicity, and BMI were used to test the association of genotype on selected end points. The threshold for statistical significance in all analyses was set at a *P* value of 0.05. Confounding was assessed in these linear regression models by age, sex, race, and BMI, and consistent results were found. Statistical analyses were performed by using STATA (version 13). Figures were constructed using GraphPad Prism (version 6).

Results {#s7}
=======

Demographic Characteristics of the Participants and Baseline Associations {#s8}
-------------------------------------------------------------------------

The baseline demographic characteristics of the 608 SUGAR-MGH participants included in the study by genotype at *TCF7L2* are summarized in [Table 1](#T1){ref-type="table"}. Nine percent of the participants included in this study were homozygous for the diabetes risk--conferring T allele, 40% were heterozygous, and 51% were homozygous for the protective C allele. Over 35% of the participants came from ethnic minority populations, participants were nearly evenly distributed between men and women, and their average BMI fell within the obese category based on the definition of the Centers for Disease Control and Prevention ([@B22]). Allele frequencies were similar to what has been previously described in the literature ([@B23]) for this variant ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1386/-/DC1)). In support of previous findings, we detected a significant association between fasting glucose level and *TCF7L2* genotype, with T--risk allele homozygotes having ∼6 mg/dL higher fasting glucose than heterozygotes or C-allele homozygotes ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1386/-/DC1)). The T--risk allele homozygotes had a 1.61 mg/dL higher baseline fasting glucose level per T allele than carriers of other genotypes ([Table 2](#T2){ref-type="table"}). Fasting insulin, proinsulin, and C-peptide concentrations were not different across the genotypes at baseline ([Table 1](#T1){ref-type="table"}).

###### 

Baseline demographics of the study participants

                                      Total       Genotype    *P* value                 
  ----------------------------------- ----------- ----------- ------------ ------------ -------
  SUGAR-MGH, *n*                      608         55          242          311          
  Male sex, *n* (%)                               25 (45.6)   125 (51.7)   142 (45.7)   0.347
  Age (years)                         48.7 ± 16   50 ± 16     50 ± 16      47 ± 16.3    0.111
  BMI (kg/m^2^)                       30.6 ± 7    29.6 ± 7    30.4 ± 6     30.9 ± 7     0.339
  Fasting glucose (mg/dL)             93.2 ± 14   98.3 ± 20   93 ± 13      92 ± 12      0.012
  Fasting insulin (mU/L)              7.2 ± 8     7.6 ± 6     7.2 ± 6      7.5 ± 6      0.867
  C-peptide (pmol/L)                  810 ± 391   820 ± 368   830 ± 390    793 ± 396    0.559
  Lifestyle-controlled T2D, *n* (%)   15 (2.5)    5 (9.1)     6 (2.5)      4 (1.3)      0.003

Data are mean ± SD unless otherwise noted. T2D, type 2 diabetes.

###### 

Magnitude of change per T allele after glipizide and metformin administration

                                                                     β-coefficient   95% CI           *P* value
  ------------------------------------------------------------------ --------------- ---------------- -----------
  Fasting glucose (mg/dL)                                            1.61            0.036, 3.18      0.04
  Glucose AOC (mg/dL)                                                160.2           −166.6, 487.1    0.34
  Fasting glucagon (pg/mL)                                           −2.5            −4.97, −0.013    0.049
  Fasting glucose V2 (mg/dL)                                         −1.02           −1.96, −0.06     0.04
  Fasting glucose V2--V1 (mg/dL)                                     −1.61           −3.22, 0.02      0.04
  GLP-1 total V1 (pmol/L)                                            1.52            0.22, 2.81       0.02
  GLP-1 active V1 (pmol/L)                                           0.96            0.35, 1.57       0.002
  Time to trough glucose at V1 adjusted for baseline glucose (min)   −7.00           −13.21, −0.79    0.027
  (Glu~0~ to Glu­~trough~)/time (mg/dL/time)                         0.023           0.002, 0.045     0.035
  (Glu~240~ to Glu~trough~)/time (mg/dL/time)                        0.024           0.004, 0.044     0.017
  Peak insulin at V1 (mU/L)                                          0.121           −3.146, 3.387    0.942
  Time to peak insulin at V1 (min)                                   −2.139          −9.998, 5.719    0.593
  Glucose trough at V1 (mg/dL)                                       −0.072          −1.477, 1.334    0.920
  Glucose trough adjusted for baseline glucose (mg/dL)               −0.727          −1.984, 0.529    0.256
  HOMA-β V1                                                          −3.35           −21.72, 15.01    0.720
  HOMA-β V2                                                          −4.34           −19.198, 10.50   0.566
  HOMA-IR V1                                                         0.068           −0.16, 0.29      0.563
  HOMA-IR V2                                                         −0.42           −0.26, 0.18      0.706
  Stumvoll index V2                                                  −0.0014         −0.004, 0.001    0.248

AOC, area over the curve; Glu~0~, baseline fasting glucose level; Glu~240~, glucose level at 240 min of OGTT; Glu~trough~, trough glucose level; V, visit.

Biochemical Response to Glipizide Differs by *TCF7L2* Genotype {#s9}
--------------------------------------------------------------

Glipizide raised serum insulin levels and lowered blood glucose levels in all participants as expected, with the insulin peak achieved at 60 min ([Fig. 1*A*](#F1){ref-type="fig"}) and blood glucose level reaching a nadir at 120 min ([Fig. 1*B*](#F1){ref-type="fig"}). Despite their higher baseline glucose levels, T--risk allele homozygotes had a similar magnitude of glucose decline after a single dose of glipizide compared with heterozygotes or C-allele homozygotes ([Table 2](#T2){ref-type="table"}). Likewise, there were no differences in insulin levels across genotype during the challenge. Glucagon levels during the glipizide challenge peaked at 180 min, at a time point after the mean blood glucose reached its lowest value. The T allele was associated with lower glucagon levels at baseline ([Table 2](#T2){ref-type="table"}), and the fasting glucagon level adjusted for baseline glucose showed a linear relationship across genotypes ([Fig. 1*C*](#F1){ref-type="fig"}). The AUC for glucagon did not achieve statistically significant differences across genotype groups.

![*A*: Change in plasma insulin across genotypes at visit 1 after glipizide administration. *B*: Change in plasma glucose across genotypes at visit 1 after glipizide administration. *C*: Change in plasma glucagon across genotypes at visit 1 after glipizide administration. Data depict mean ± SEM, *n* = 608 (CC = 311, CT = 242, TT = 55).](dc171386f1){#F1}

Ninety-four (30%) CC homozygotes, 75 (31%) CT heterozygotes, and 18 (33%) TT homozygotes terminated the glipizide challenge early due to hypoglycemia or hypoglycemia-related symptoms, without statistically significant differences between the groups (*P* = 0.935). However, overall, participants who completed the entire glipizide challenge had higher fasting glucose values prior to receiving glipizide and higher trough glucose during the glipizide challenge than did participants who terminated the glipizide challenge because of hypoglycemia or hypoglycemia-related symptoms.

We evaluated predefined phenotypes that capture the acute pharmacological and physiological responses to the medications used in the SUGAR-MGH and characterized clinically relevant and pharmacodynamic parameters. There were no significant differences in glucose trough adjusted for baseline glucose level by genotype at *TCF7L2* ([Table 2](#T2){ref-type="table"}). There were significant genotype-driven differences in the time to glucose trough after glipizide administration, which was shorter by 7 min per T allele after adjustment for baseline glucose level ([Table 2](#T2){ref-type="table"}).The T allele was also associated with a steeper slope in glucose drop between the start of the visit (0 min) and the trough level ([Table 2](#T2){ref-type="table"}). There were also significant differences across genotypes in the upward slope of glucose recovery between the glucose trough and the end of the study visit (240 min) with the T allele associated with a steeper slope ([Table 2](#T2){ref-type="table"}). There were no genotype-driven differences in any of the insulin-based predefined end points ([Table 2](#T2){ref-type="table"}).

Biochemical Response to Metformin Differs by *TCF7L2* Genotype {#s10}
--------------------------------------------------------------

Although there were no differences across genotypes in fasting glucose levels at visit 2 after four doses of metformin, the T allele was associated with lower fasting glucose levels at visit 2 after adjusting for the fasting glucose level at visit 1 ([Table 2](#T2){ref-type="table"}). The T allele was also associated with a greater drop in glucose between visits 1 and 2 ([Fig. 1*C*](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). There were no differences in fasting insulin levels or in surrogate measures of β-cell function and insulin resistance (IR) by homeostasis model assessment (HOMA-β or HOMA-IR) ([@B24]) between visits 1 and 2 and in the modified Stumvoll index ([@B25]) by genotype at *TCF7L2* ([Table 2](#T2){ref-type="table"}).

Alterations in Incretin Levels During the OGTT {#s11}
----------------------------------------------

There were no genotype-driven differences in glucose or insulin levels during the OGTT ([Fig. 2*A* and *B*](#F2){ref-type="fig"}). Incretin levels were measured in a subset of participants (50 from each genotype group at *TCF7L2* rs7903146). The baseline characteristics of this subset of participants were similar to those observed in the overall cohort, suggesting that they were drawn from the same underlying distribution. The T allele was associated with higher baseline total and active GLP-1 at visit 1, even after adjusting for age, sex, race, BMI, and fasting glucose level ([Table 2](#T2){ref-type="table"}). At visit 2, the T allele was again associated with higher fasting total and active GLP-1 levels, and these differences remained across all time points of the OGTT, with a higher AUC for both total and active GLP-1 levels (*P* \< 0.005 for both). These differences were mainly driven by TT homozygotes ([Fig. 2*C* and *D*](#F2){ref-type="fig"}). Although there were no differences observed in GIP levels at baseline in visit 1, during the OGTT in visit 2 the T allele was associated with lower GIP levels (*P* = 0.02) ([Fig. 2*E*](#F2){ref-type="fig"}).

![*A* and *B*: *n* = 608 (CC = 311, CT = 242, TT = 55). *A*: Change in plasma glucose across the various time points of the OGTT at visit 2 after four doses of metformin. *B*: Change in plasma insulin across the various time points of the OGTT at visit 2 after four doses of metformin. *C--E*: *n* = 150 (CC = 50, CT = 50, TT = 50). *C*: Change in plasma GLP-1 (total) across the various time points of the OGTT at visit 2 after four doses of metformin. *D*: Change in plasma GLP-1 (active) across the various time points of the OGTT at visit 2 after four doses of metformin. *E*: Change in plasma GIP across the various time points of the OGTT at visit 2 after four doses of metformin. Data depict mean ± SEM.](dc171386f2){#F2}

Conclusions {#s12}
===========

Using a novel prospective human pharmacogenetic resource, which is free of the uncontrolled nature of retrospective clinical data sets, we have shown that the type 2 diabetes--associated variant rs7903146 in *TCF7L2* influences the acute response to both glipizide and metformin in persons free of overt diabetes. In parallel, through pharmacological perturbations and hormonal measurements we have been able to generate additional evidence in support of altered incretin signaling as a potential mechanism by which *TCF7L2* increases type 2 diabetes risk. We have demonstrated that SUGAR-MGH is adequately powered to detect differences, because participants who carried the high-risk T allele at rs7903146 in the *TCF7L2* gene had a higher fasting glucose level at baseline before the glycemic perturbations, a finding that is consistent with previous work ([@B26]). Despite this higher baseline, TT homozygotes achieved a trough glucose level faster than CC homozygotes after glipizide administration and also demonstrated a significantly steeper slope to glucose trough. The T allele was associated with lower glucagon levels at baseline even after adjusting for baseline glucose level. Because this measure excludes participants who received rescue carbohydrate for hypoglycemia, it likely reflects the endogenous response to hypoglycemia driven by counter-regulatory hormones. In terms of metformin response, high-risk T-allele carriers had a lower fasting glucose level after having received a short course of metformin, as well a greater decrease in fasting glucose levels from visit 1 to visit 2. These findings suggest that they had a better response to metformin than subjects who did not carry the high-risk allele, and the persistence of a significant difference after adjustment for baseline glucose at visit 1 suggests that the drug response is driven by genotype and not by the higher baseline glucose. Although the clinical implications of the individual end points may be subtle, it is noteworthy that we are able to demonstrate significant differences based on genotype just after a single dose of 5 mg of glipizide and after four doses of 500 mg of metformin.

With regard to the mechanism at this locus, high-risk T-allele carriers also had lower glucagon levels at baseline, ruling out a primary effect on higher glucagon levels as the process by which *TCF7L2* increases type 2 diabetes risk and suggesting that lower glucagon levels in T-allele carriers are a compensatory response for a primary effect on fasting glucose. This may also explain why rates of hypoglycemia were not significantly higher in TT carriers. Lower glucagon levels can also be explained by reduced expression of proglucagon in α-cells or altered post-translational processing to glucagon. Our study adds to a mounting body of evidence that suggests that the α-cell may play a significant role in *TCF7L2*-mediated diabetes risk ([@B27],[@B28]). In a study of 120 individuals evenly distributed between TT and CC homozygotes at this locus, TT carriers exhibited impaired the suppression of glucagon after an oral challenge, suggesting that genetic variation in *TCF7L2* is associated with impaired postprandial suppression of glucagon ([@B29]).

In a small subset of our participants, we observed that the *TCF7L2* high-risk genotype is associated with higher total and active GLP-1 levels at baseline and across all points of the OGTT; together with the lack of a detectable change in glucose or insulin levels across genotypes, this observation is suggestive of GLP-1 resistance in these individuals. These findings expand on the existing knowledge base ([@B30]--[@B32]) and continue to implicate altered incretin signaling as a potential contributory mechanism for increased *TCF7L2*-associated type 2 diabetes risk.

With the exception of some monogenic forms of diabetes ([@B33]), few pharmacogenetic studies of metformin and sulfonylurea response have been published. Small-scale studies have shown differences in sulfonylurea metabolism, but studies on actual measured drug response are conflicting ([@B12]). Similarly, despite the status of metformin as the most commonly prescribed medication for type 2 diabetes, few pharmacogenetic studies of its response have been published. Two genome-wide association studies have implicated common variants in the genes *ATM* ([@B10]) and *SLC2A2* ([@B11]) in metformin response, but the physiological or pharmacological implications of these findings still remain unclear. Several studies have focused on the rs7903146 variant in *TCF7L2* as a determinant of drug response, given its relatively strong impact on type 2 diabetes risk among common variants. In a large GoDARTS retrospective study of subjects with type 2 diabetes, of 901 users of sulfonylureas, homozygotes for the type 2 diabetes T risk allele at *TCF7L2* rs7903146 were less likely to respond to sulfonylureas, with an odds ratio of failure of 1.73 (95% CI 1.11, 2.70; *P* = 0.015), which is in the opposite direction to our findings in the SUGAR-MGH. Furthermore, no effect of the *TCF7L2* genotype was observed in 945 individuals evaluated for metformin response ([@B34]), which again is in contrast to our present results. Several reasons may explain these discrepancies. Although the GoDARTS authors were careful to account for potential confounders, the limitations inherent to an observational study make it susceptible to prescriber bias, which may influence treatment and dosage decisions and therefore response. Furthermore, it is possible that the genotype has a differential effect in subjects in whom diabetes has not yet developed compared with subjects with established type 2 diabetes, in whom some degree of β-cell failure may have already occurred. This concept was demonstrated in a study of 1,576 subjects with varying degrees of glycemia, in whom the level of glycemia determined the effect of *TCF7L2* variation on surrogate measures of insulin secretion ([@B35]). Under this paradigm, if variation at *TCF7L2* impairs β-cell function and predisposes β-cells to failure, sulfonylureas could be more effective in risk allele carriers in whom β-cell mass is preserved early in the type 2 diabetes disease course, but become less effective as the disease progresses. Similarly, metformin might be more effective in this at-risk group before pathological changes have had the opportunity to occur, although the DPP results suggest that this effect may not be sustained.

Numerous investigations have been conducted to understand the molecular mechanisms by which *TCF7L2* exerts its functions in pancreatic and intestinal endocrine cells ([@B36]--[@B38]). The *TCF7L2* transcription factor binds to the promoter of the proglucagon gene, which in turn encodes glucagon, GLP-1, and GLP-2 ([@B39]). The total form of GLP-1, GLP-1 (7--36) NH~2~, is rapidly metabolized to the active form GLP-1 (9--36) NH~2~, which is the predominant form of GLP-1 in postprandial plasma because of its relatively slower clearance ([@B40]). The WNT signaling pathway is required for the normal development of pancreatic islets and also regulates GLP-1 expression and secretion in the intestinal L cell. Therefore, one early hypothesis postulated that polymorphisms in *TCF7L2* could reduce incretin-stimulated insulin secretion and thereby increase type 2 diabetes risk. However, rather than showing a deficiency in GLP-1 production, previous studies have demonstrated evidence of impaired incretin-mediated insulin response in individuals who carry the high-risk allele at *TCF7L2* ([@B30],[@B32],[@B38],[@B41]). Consistent with our results, Schäfer et al. ([@B30]) reported normal GLP-1 secretion but reduced effect of GLP-1 upon stimulation of insulin secretion in rs7903146 T-allele carriers, indicating a state of relative incretin resistance. Our results expand on current knowledge by demonstrating an impaired incretin effect (higher glucose levels despite higher GLP-1 levels and reduced GIP levels) in a clinical research study of a multiethnic cohort of individuals who have risk factors for type 2 diabetes but are naive to antidiabetic therapy.

A limitation of our study design is the lack of an OGTT prior to the administration of metformin. Although this was a consideration when designing the study, logistical considerations that would enable recruitment of a large cohort with excellent retention rates, and short duration did not make this feasible. Therefore, although we are able to effectively demonstrate genotype-driven differences in metformin response, we are unable to provide a more refined explanation based on a dynamic glucose challenge. We emphasize that SUGAR-MGH, although providing a unique pharmacogenetic resource to probe the influence of genetic variation on physiology and the response to metformin and glipizide, was not designed to be a clinical trial seeking to modify or expand current treatment indications for metformin or sulfonylureas. Rather, it allows for the ongoing systematic evaluation of how known genetic variants modify acute antidiabetic drug responses in humans. Our study provides clinically relevant results that genetic variation can alter the response to therapy in type 2 diabetes. Our findings build on a growing body of evidence to suggest that raising incretin levels pharmacologically in carriers of *TCF7L2* variants who have a pathological background of incretin resistance may be a less desirable therapeutic choice. For instance, testing of DPP-IV inhibitors, which block the degradation of incretins, could be of clinical relevance in this population ([@B42]). In sum, a unique data set like SUGAR-MGH enables the study of genetic determinants of drug response, as a crucial test of whether genetically based precision medicine might predict a therapeutic benefit in the clinical management of patients. Further studies are needed to better understand the physiological and clinical impacts of specific genetic variants to help guide the design of prospective pharmacogenetic clinical trials.
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